Answers are grounded in this paper and cite their sources.
Muscle mass is central to physical function and metabolic health, but can decrease with disease, aging and weight loss interventions. As weight loss interventions become more widely used, agents that preserve or increase muscle mass are needed. To identify such therapeutic opportunities, we perform genome-wide association meta-analyses of arm, leg, trunk and total lean mass measured by dual-energy X-ray absorptiometry, a widely used method to estimate muscle mass. We identify 63 loci, including a rare missense variant in MSTN (p.Ile225Thr, rs143242500), which has the largest effect on leg lean mass ( β = 0.28 SD [95% CI: 0.19, 0.37], P = 1.9 × 10 -9 ). MSTN encodes myostatin, a negative regulator of skeletal muscle mass and a therapeutic target for muscle wasting disorders. Here, we identify a genome-wide significant association at MSTN in humans and characterize its functional consequences, providing genetic evidence that may inform the long-term systemic effects of myostatin inhibition.
No takes yet. Share an insight, caveat, or question.
Larusdottir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: